CN105363025A - Pharmaceutical formulation for treating cardiovascular diseases - Google Patents
Pharmaceutical formulation for treating cardiovascular diseases Download PDFInfo
- Publication number
- CN105363025A CN105363025A CN201510764978.XA CN201510764978A CN105363025A CN 105363025 A CN105363025 A CN 105363025A CN 201510764978 A CN201510764978 A CN 201510764978A CN 105363025 A CN105363025 A CN 105363025A
- Authority
- CN
- China
- Prior art keywords
- accounts
- radix
- pharmaceutical formulation
- rhizoma
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 16
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 9
- 241000208340 Araliaceae Species 0.000 claims abstract description 8
- 102000016938 Catalase Human genes 0.000 claims abstract description 8
- 108010053835 Catalase Proteins 0.000 claims abstract description 8
- 241000628997 Flos Species 0.000 claims abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 229960003180 glutathione Drugs 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 239000011701 zinc Substances 0.000 claims abstract description 8
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 8
- 229940105657 catalase Drugs 0.000 claims abstract description 5
- 241000746375 Andrographis Species 0.000 claims description 7
- 102000003992 Peroxidases Human genes 0.000 claims description 7
- 235000003969 glutathione Nutrition 0.000 claims description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 7
- 229940072417 peroxidase Drugs 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 206010003225 Arteriospasm coronary Diseases 0.000 abstract description 2
- 102000001554 Hemoglobins Human genes 0.000 abstract description 2
- 108010054147 Hemoglobins Proteins 0.000 abstract description 2
- 239000003633 blood substitute Substances 0.000 abstract description 2
- 230000001631 hypertensive effect Effects 0.000 abstract description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 241001522232 Pinellia ternata Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical formulation for treating cardiovascular diseases. The pharmaceutical formulation consists of flos chrysanthemi, lycium chinensis, card3 gene, zinc, salvia miltiorrhiza, radix notoginseng, ginseng, polygonum multiflorum, ligusticum wallichii, angelica sinensis, rhizoma alismatis, cortex phellodendri, pinellia ternata, herba andrographitis, panax notoginseng, catalase, vitamin E, glutathione and sodium hydrosulfite. Compared with the prior art, the pharmaceutical formulation disclosed by the invention can inhibit, relieve and treat cardiovascular diseases, prevent the injury of vascular endothelial cells, reduce hypertensive responses, prevent coronary spasm and keep cardiac functions, and the pharmaceutical formulation can effectively reduce the cardiovascular side effects of a hemoglobin-based oxygen carrier; and the pharmaceutical formulation, which can overcome shortcomings of existing blood substitutes which cause the cardiovascular side effects, has values of popularization and application.
Description
Technical field
The present invention relates to a kind of disease curative composition formula, particularly relate to a kind of pharmaceutical formulation of Cardiovarscular.
Background technology
So-called cardiovascular and cerebrovascular disease is exactly that cardiovascular and cerebrovascular disease are referred to as, and makes a general reference because ischemic or hemorrhage occur for the heart that hyperlipemia, blood are sticky, atherosclerosis, hypertension etc. cause, brain and body tissue.A kind of serious threat mankind, the particularly commonly encountered diseases of more than 50 years old middle-aged and elderly people health, even if apply treatment means most advanced, perfect at present, the cerebrovas-cularaccident survivor of more than 50% still can be had to live can not take care of oneself completely, the number of cardiovascular and cerebrovascular disease is died from every year up to 1,500 ten thousand people in the whole world, occupies the various cause of the death the first.Therefore, need a kind of new medicine for suppressing, alleviating and Cardiovarscular.
Summary of the invention
Object of the present invention is just the pharmaceutical formulation providing a kind of Cardiovarscular in order to solve the problem.
The present invention is achieved through the following technical solutions above-mentioned purpose:
The present invention is made up of Flos Chrysanthemi, Fructus Lycii, card3 gene, zinc, Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Ginseng, Radix Polygoni Multiflori, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Alismatis, Cortex Phellodendri, the Rhizoma Pinelliae, Herba Andrographis, Radix Notoginseng, catalase, peroxidase, vitamin E, glutathion and sodium dithionite.
Particularly, described Flos Chrysanthemi accounts for 5%, described Fructus Lycii accounts for 8%, described card3 gene accounts for 1%, described zinc accounts for 2.5%, described Radix Salviae Miltiorrhizae accounts for 10%, described Radix Notoginseng accounts for 5%, described Radix Ginseng accounts for 2%, described Radix Polygoni Multiflori accounts for 3%, described Rhizoma Chuanxiong accounts for 3%, described Radix Angelicae Sinensis accounts for 4%, described Rhizoma Alismatis accounts for 4%, described Cortex Phellodendri accounts for 6%, the described Rhizoma Pinelliae accounts for 15%, described Herba Andrographis accounts for 10%, described Radix Notoginseng accounts for 10%, described catalase accounts for 1.5%, described peroxidase accounts for 2.5%, described vitamin E accounts for 3.5%, described glutathion accounts for 2%, described sodium dithionite accounts for 2%.
Beneficial effect of the present invention is:
The present invention is a kind of pharmaceutical formulation of Cardiovarscular, compared with prior art, the present invention can suppress, alleviate and Cardiovarscular, can vascular endothelial cell damage be prevented, reduce hyper tensive reactions, prevent coronary vasospasm, maintain heart body, effectively can reduce the cardiovascular side effects of hemoglobin O_2 carrier, the defect that existing blood substitute exists cardiovascular side effects can be overcome, there is the value applied.
Detailed description of the invention
The invention will be further described below:
The present invention is made up of Flos Chrysanthemi, Fructus Lycii, card3 gene, zinc, Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Ginseng, Radix Polygoni Multiflori, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Alismatis, Cortex Phellodendri, the Rhizoma Pinelliae, Herba Andrographis, Radix Notoginseng, catalase, peroxidase, vitamin E, glutathion and sodium dithionite.
Particularly, described Flos Chrysanthemi accounts for 5%, described Fructus Lycii accounts for 8%, described card3 gene accounts for 1%, described zinc accounts for 2.5%, described Radix Salviae Miltiorrhizae accounts for 10%, described Radix Notoginseng accounts for 5%, described Radix Ginseng accounts for 2%, described Radix Polygoni Multiflori accounts for 3%, described Rhizoma Chuanxiong accounts for 3%, described Radix Angelicae Sinensis accounts for 4%, described Rhizoma Alismatis accounts for 4%, described Cortex Phellodendri accounts for 6%, the described Rhizoma Pinelliae accounts for 15%, described Herba Andrographis accounts for 10%, described Radix Notoginseng accounts for 10%, described catalase accounts for 1.5%, described peroxidase accounts for 2.5%, described vitamin E accounts for 3.5%, described glutathion accounts for 2%, described sodium dithionite accounts for 2%.
When the present invention uses, water Flos Chrysanthemi, Fructus Lycii, Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Ginseng, Radix Polygoni Multiflori, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Alismatis, Cortex Phellodendri, the Rhizoma Pinelliae, Herba Andrographis and Radix Notoginseng being added 5 times amount is brewed into 1 times amount, filter out residue after cooling, precipitate, get supernatant, will add card3 gene, zinc, catalase, peroxidase, vitamin E, glutathion and sodium dithionite mixing rear support medicament in supernatant, usage is adult one time 2 milliliters, one day twice, a point morning and evening took.
More than show and describe ultimate principle of the present invention and principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and description just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.Application claims protection domain is defined by appending claims and equivalent thereof.
Claims (2)
1. a pharmaceutical formulation for Cardiovarscular, is characterized in that: be made up of Flos Chrysanthemi, Fructus Lycii, card3 gene, zinc, Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Ginseng, Radix Polygoni Multiflori, Rhizoma Chuanxiong, Radix Angelicae Sinensis, Rhizoma Alismatis, Cortex Phellodendri, the Rhizoma Pinelliae, Herba Andrographis, Radix Notoginseng, catalase, peroxidase, vitamin E, glutathion and sodium dithionite.
2. the pharmaceutical formulation of Cardiovarscular according to claim 1, it is characterized in that: described Flos Chrysanthemi accounts for 5%, described Fructus Lycii accounts for 8%, described card3 gene accounts for 1%, described zinc accounts for 2.5%, described Radix Salviae Miltiorrhizae accounts for 10%, described Radix Notoginseng accounts for 5%, described Radix Ginseng accounts for 2%, described Radix Polygoni Multiflori accounts for 3%, described Rhizoma Chuanxiong accounts for 3%, described Radix Angelicae Sinensis accounts for 4%, described Rhizoma Alismatis accounts for 4%, described Cortex Phellodendri accounts for 6%, the described Rhizoma Pinelliae accounts for 15%, described Herba Andrographis accounts for 10%, described Radix Notoginseng accounts for 10%, described catalase accounts for 1.5%, described peroxidase accounts for 2.5%, described vitamin E accounts for 3.5%, described glutathion accounts for 2%, described sodium dithionite accounts for 2%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510764978.XA CN105363025A (en) | 2015-11-11 | 2015-11-11 | Pharmaceutical formulation for treating cardiovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510764978.XA CN105363025A (en) | 2015-11-11 | 2015-11-11 | Pharmaceutical formulation for treating cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105363025A true CN105363025A (en) | 2016-03-02 |
Family
ID=55365977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510764978.XA Pending CN105363025A (en) | 2015-11-11 | 2015-11-11 | Pharmaceutical formulation for treating cardiovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105363025A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113057309A (en) * | 2021-04-26 | 2021-07-02 | 广东美味源香料股份有限公司 | Modified monosodium glutamate paste seasoning and preparation method thereof |
-
2015
- 2015-11-11 CN CN201510764978.XA patent/CN105363025A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113057309A (en) * | 2021-04-26 | 2021-07-02 | 广东美味源香料股份有限公司 | Modified monosodium glutamate paste seasoning and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102397351A (en) | Traditional Chinese medicinal composition for treating insomnia | |
| CN103830431A (en) | Traditional Chinese medicine composition for promoting hair melanin production | |
| CN108852998A (en) | Improve active component, face mask cream and the preparation method of hormone face, lead mercury poisoning face | |
| CN104138429A (en) | Medicine for treating arrhythmia heart blood insufficiency type coronary heart disease | |
| CN105363025A (en) | Pharmaceutical formulation for treating cardiovascular diseases | |
| CN102988608B (en) | Chinese medicinal composition for treating alopecia areata | |
| CN104740131A (en) | Traditional Chinese medicinal oral liquid for treating apoplexy hemiplegia | |
| CN101467946A (en) | Repair powder for nursing face | |
| CN104644857A (en) | Traditional Chinese medicine formula for treating acnes | |
| CN103055055A (en) | Traditional Chinese medicine for treating skin diseases | |
| CN104721791A (en) | Pharmaceutical formulation for treating cardiovascular and cerebrovascular diseases | |
| CN102552711B (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN104225264A (en) | Traditional Chinese medicine decoction for treating aplastic anemia | |
| CN101732622A (en) | Chinese medicament for treating ischidrosis | |
| CN105194121A (en) | External solution for treating onychomycosis | |
| CN104547732A (en) | Traditional Chinese medicine composition for treating acne | |
| CN104547124A (en) | Plaster for treating allergic dermatitis | |
| CN104138456A (en) | Medicine for treating arrhythmia heart blood stasis type coronary heart disease | |
| CN102940833B (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
| CN101239095B (en) | Method for preparing embolism-extinguishing enteric-coated capsule | |
| CN105287774A (en) | Traditional Chinese medicine composition for treating facial seborrheic dermatitis | |
| CN103055282A (en) | Medicine for treating leucoderma | |
| CN105031319A (en) | External traditional Chinese medicine for removing scar | |
| CN104224643A (en) | Hair-blacking shampoo | |
| CN104800599A (en) | Traditional Chinese medicinal composition for treating deficiency of kidney-yin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Yue Document name: Notice of Reexamination |
|
| DD01 | Delivery of document by public notice | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160302 |
|
| RJ01 | Rejection of invention patent application after publication |